Legacy Capital Group California Inc. bought a new position in Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) in the 2nd quarter, according to its most recent disclosure with the SEC. The firm bought 10,301 shares of the company’s stock, valued at approximately $162,000.
Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Dimensional Fund Advisors LP raised its holdings in Takeda Pharmaceutical by 0.4% in the first quarter. Dimensional Fund Advisors LP now owns 143,115 shares of the company’s stock worth $2,359,000 after buying an additional 616 shares during the last quarter. Northwestern Mutual Wealth Management Co. raised its holdings in Takeda Pharmaceutical by 28.7% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 2,976 shares of the company’s stock worth $46,000 after buying an additional 663 shares during the last quarter. EverSource Wealth Advisors LLC raised its holdings in Takeda Pharmaceutical by 70.7% in the first quarter. EverSource Wealth Advisors LLC now owns 1,757 shares of the company’s stock worth $29,000 after buying an additional 728 shares during the last quarter. Checchi Capital Advisers LLC raised its holdings in Takeda Pharmaceutical by 5.5% in the second quarter. Checchi Capital Advisers LLC now owns 14,490 shares of the company’s stock worth $228,000 after buying an additional 758 shares during the last quarter. Finally, BNP Paribas Arbitrage SNC raised its holdings in Takeda Pharmaceutical by 37.5% in the second quarter. BNP Paribas Arbitrage SNC now owns 2,781 shares of the company’s stock worth $44,000 after buying an additional 759 shares during the last quarter. 2.65% of the stock is owned by hedge funds and other institutional investors.
Takeda Pharmaceutical Stock Up 1.7 %
TAK opened at $13.95 on Friday. The company has a quick ratio of 0.55, a current ratio of 1.04 and a debt-to-equity ratio of 0.62. The firm has a 50 day moving average price of $14.81 and a 200-day moving average price of $15.42. Takeda Pharmaceutical Company Limited has a twelve month low of $13.19 and a twelve month high of $17.15. The stock has a market capitalization of $44.15 billion, a price-to-earnings ratio of 19.38, a PEG ratio of 4.81 and a beta of 0.64.
Analyst Upgrades and Downgrades
Separately, JPMorgan Chase & Co. decreased their target price on shares of Takeda Pharmaceutical from $14.20 to $14.00 in a report on Friday, September 1st.
Takeda Pharmaceutical Profile
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
- Five stocks we like better than Takeda Pharmaceutical
- What to Know About Investing in Penny Stocks
- S&P 500’s Whirlwind: Big gains, warning whispers & tactical moves
- How to Invest in Esports
- MarketBeat Week in Review – 11/13 – 11/17
- Election Stocks: How Elections Affect the Stock Market
- 3 large caps with red hot RSIs with upside
Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.